SR One and Roche Venture Fund-backed Pandion Therapeutics will use the proceeds from the offering to advance a lead drug candidate for ulcerative colitis.

Pandion Therapeutics, a US-based autoimmune disease drug developer backed by conglomerate Access Industries and pharmaceutical firms Roche and GlaxoSmithKline (GSK), has filed for a $75m initial public offering. Founded in 2016, Pandion is utilising protein engineering to develop treatments for autoimmune diseases. Part of the proceeds from the IPO will support phase 1a and phase…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.